scan

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

DeFi Deep Dive — Covalent, Blockchain Data Unifier

One of the problems facing Web 3.0 is the unification of scattered decentralized networks. Covalent is addressing this issue. It gives developers access to smart contract data to survey the entire blockchain ecosystem.Sponsored Sponsored Covalent makes it easier for investors to glean insights and performance of digital assets. This is done through its unified API (application programming interface) that indexes blockchains. These range from NFTs to DeFi protocols. A brief history Ganesh Swami and Levi Aul started Covalent, expanding to a 35-person team. Across all personnel, they have extensive cumulative

Q&A: How Blockchain Could Transform the Art Industry

The art world has had a tough time lately. The coronavirus pandemic has forced many galleries and museums to close, with sales of premium pieces also affected.But there could be a solution that helps the industry get back on its feet and achieve much-needed digitization: blockchain. Here, we talk to Niko Kipouros, founder and CEO of 4ARTechnologies, about how this technology could transform the way we purchase and own artwork — and even ensure that the provenance and authenticity of masterpieces are never doubted.1. What are the biggest challenges facing